Figure S1. Inhibitory effect of 5-FU on LLC.LG and A549 cell survival based on predicted IC_{50}. Survival of LLC. LG and A549 cells affected by 5-FU treatment was tested using the sulforhodamine B assay at various concentrations (0.0375-0.075 μM for LLC.LG and 2.34-4.68 μM for A549 cells). The cell survival rate was ~70% in response to 0.0375 and 3.125 μM 5-FU for LLC. LG and A549 cells, respectively. Values are expressed as the mean ± SD (n=3). 5-FU, 5-fluorouracil.



Figure S2. Prediction of the impact of upregulated Slug expression on epithelial-mesenchymal transition, non-small cell lung carcinoma and apoptosis of non-small-cell lung cancer cells. The symbol in the Ingenuity Pathway Analysis system for Slug is SNAI2. The molecules involved are presented in an organic layout.



Figure S3. Prediction of the impact of upregulated vimentin expression on epithelial-mesenchymal transition, non-small cell lung carcinoma and apoptosis of non-small-cell lung cancer cells. The symbol in the Ingenuity Pathway Analysis system for vimentin is VIM. The molecules involved are presented in an organic layout.



Figure S4. Prediction of the impact of downregulated E-cadherin expression on epithelial-mesenchymal transition, non-small cell lung carcinoma and apoptosis of non-small-cell lung cancer cells. The symbol in the ingenuity pathway analysis system for E-cadherin is CDH1. The molecules involved are presented in an organic layout.